Neovasc Inc (US) (NVCN) Receives Daily Coverage Optimism Score of 0.03
News headlines about Neovasc Inc (US) (NASDAQ:NVCN) (TSE:NVC) have trended somewhat positive this week, according to Accern Sentiment Analysis. The research firm identifies positive and negative media coverage by reviewing more than twenty million news and blog sources in real-time. Accern ranks coverage of companies on a scale of negative one to one, with scores closest to one being the most favorable. Neovasc Inc (US) earned a news sentiment score of 0.03 on Accern’s scale. Accern also assigned media headlines about the medical equipment provider an impact score of 47.2043109735765 out of 100, indicating that recent media coverage is somewhat unlikely to have an impact on the company’s share price in the immediate future.
These are some of the news stories that may have impacted Accern’s scoring:
- Neovasc (NVCN) Cut to Strong Sell at ValuEngine (americanbankingnews.com)
- Gratifying Stocks- Neovasc Inc. (NASDAQ:NVCN) a Medical … – The Stock Street (press release) (thestreetpoint.com)
- Notable Trader’s Round Up: Ares Capital Corporation, (NASDAQ: ARCC), Neovasc Inc., (NASDAQ: NVCN), 3D … – Stocks In The News (press release) (tradingnewsnow.com)
- Morning Buzz Neovasc Inc. (NASDAQ:NVCN) a Medical Appliances … – The Stock Street (press release) (thestreetpoint.com)
- Neovasc, Inc. :NVCN-US: Earnings Analysis: Q3, 2017 By the Numbers : November 29, 2017 (finance.yahoo.com)
Several analysts recently commented on the stock. ValuEngine downgraded shares of Neovasc Inc (US) from a “sell” rating to a “strong sell” rating in a research report on Friday. Zacks Investment Research downgraded shares of Neovasc Inc (US) from a “buy” rating to a “hold” rating in a research report on Wednesday, October 18th. One analyst has rated the stock with a sell rating, one has issued a hold rating and three have assigned a buy rating to the company. The company presently has a consensus rating of “Hold” and an average target price of $5.19.
Neovasc Inc (NASDAQ NVCN) traded down $0.05 on Tuesday, hitting $0.73. 365,300 shares of the company traded hands, compared to its average volume of 522,587. Neovasc Inc has a twelve month low of $0.70 and a twelve month high of $3.34. The firm has a market capitalization of $61.56, a PE ratio of 2.89 and a beta of -0.07.
TRADEMARK VIOLATION NOTICE: “Neovasc Inc (US) (NVCN) Receives Daily Coverage Optimism Score of 0.03” was first reported by TheOlympiaReport and is the property of of TheOlympiaReport. If you are viewing this article on another domain, it was stolen and reposted in violation of U.S. and international trademark and copyright laws. The correct version of this article can be viewed at https://theolympiareport.com/2017/12/05/neovasc-inc-us-nvcn-receives-daily-coverage-optimism-score-of-0-03.html.
About Neovasc Inc (US)
Neovasc Inc (Neovasc) is a specialty medical device company. The Company develops, manufactures and markets products for the cardiovascular marketplace. The Company’s segment is the development, manufacture and marketing of medical devices. Its products include the Tiara technology in development for the transcatheter treatment of mitral valve disease, the Neovasc Reducer for the treatment of refractory angina, and tissue products.
Receive News & Ratings for Neovasc Inc (US) Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Neovasc Inc (US) and related companies with Analyst Ratings Network's FREE daily email newsletter.